Triple Regimens Archives

FDA Approves New Kyprolis Combination Regimen

Approvals, Blockbusters, Dexamethasone, Dosing, Expanded Approval, FDA, FDA/Regulatory, Once-Weekly Dosing, Prescribing Information, Relapse/Refractory Multiple Myeloma, Therapeutics, Triple Regimens, Twice-Weekly Dosing

The U.S. Food and Drug Administration approved the expansion of Amgen’s Kyprolis (carfilzomib) U.S. prescribing information to include the product’s use in combination with Darzalex (daratumumab) plus dexamethasone (DKd) in two dosing regimens – once weekly and twice weekly – for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.

Karyopharm’s Xpovio Hits the Mark in Phase III Multiple Myeloma Trial

Business, Clinical Trials, Clinical Trials, Multiple myeloma, Progression-Free Survival (PFS), R&D, Research & Development, Shares, Triple Regimens

Shares of Karyopharm Therapeutics soared after the company posted positive Phase III results in multiple myeloma and announced plans for a regulatory submission in the second quarter of 2020 for a combination of Xpovio, Velcade and Dexamethasone.

Celgene Receives European Commission Approvals for Revlimid and Imnovid-Based Triplet Combination Regimens for Multiple Myeloma

Approvals, Clinical Data, European Commission, FDA/Regulatory, Multiple myeloma, Regimens, Triple Regimens

Celgene Corporation announced that the European Commission approved two new triplet regimens based on the company’s proprietary IMiD treatments, Revlimid (lenalidomide) and Imnovid (pomalidomide).